Back

Pipeline

Debiopharm International’s projects cover all molecule type proteins, peptides, small molecules

Oncology Infectious decease

Oncology

Program Indication Mode of Action
Discovery Preclinical Phase I Phase II Phase III
xevinapant
_ xevinapant (Debio 1143)
Head & Neck Cancer – IAP antagonist
IAP antagonist
Merck
Debio 0123
_ Debio 0123
Oncology – Wee1 kinase inhibitor
Wee1 kinase inhibitor
_ Debio 0123 +lunresertib
Advanced solid tumors – Wee1 & PKMYT1 inhibitor
Wee1 & PKMYT1 inhibitor
Repare
Debio 4126
_ Debio 4126
Acromegaly – Synthetic Somatostatin analogue
Synthetic Somatostatin analogue
Debio 0228/0328
_ Debio 0328
Oncology Diagnostic – CAIX-targeted radioligand
CAIX-targeted radioligand
_ Debio 0228
Oncology – CAIX-targeted radiotherapy
CAIX-targeted radiotherapy
ITM
ITM: ITM Isotope Technology Munich SE
Repare: Repare Therapeutics
Merck: Merck KGaA

Infectious decease

Program Indication Mode of Action
Discovery Preclinical Phase I Phase II Phase III
afabicin (Debio 1450)
_ afabicin (Debio 1450)
Bone & joint infections – FabI inhibitor
FabI inhibitor
ODD/FT/QIDP
_ afabicin (Debio 1450)
ABSSSI – FabI inhibitor
FabI inhibitor
FT/QIDP
Debio 1453
_ Debio 1453
N. gonorrhoeae – Fabl inhibitor
Fabl inhibitor
CARB-X
Debio 1455
_ Debio 1455
Inflammatory Bowel Disease – Microbiome remodeling
Microbiome remodeling
ODD: Orphan Drug Designation
FT: Fast-Track
QIDP: Qualified Infectious Disease Product
CARB-X: CARB-X grant
  • Want to know more about our pipeline?

    Discover our 18 studies from discovery to phase III in oncology and bacterial infections

    Discover the full pipeline
  • Want to partner with us?

    Do you have a promising oncology or antibacterial compound? Or are you interested in commercializing one of our programs?

    Contact us